C3-Targeting dsRNA Compositions for Noninvasive Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternative and combination therapies for subjects with complement component C3-associated diseases, as existing treatments are time-consuming and invasive, and there are limited options available for managing inappropriate complement system activation that leads to various pathological conditions.
Innovation Solution
The development of double-stranded ribonucleic acid (dsRNA) agents that target and inhibit the expression of the complement component C3 gene through RNA-induced silencing complex (RISC)-mediated cleavage, using specific dsRNA compositions with varying degrees of nucleotide similarity and modifications to effectively reduce C3 expression in cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing complement system therapies are used, then complement activation is inhibited, but the treatments are time-consuming and invasive with limited options
Solution Approach 1:
The patent replaces mechanical/invasive complement inhibition methods with RNA interference technology. The dsRNA molecules specifically target and silence complement component genes (C1q, C2, C4, C3, Bf, B, C5, C6, C7, C8, C9, Factor H, Factor I) through molecular recognition and RISC-mediated cleavage, eliminating the need for time-consuming invasive procedures while maintaining therapeutic effectiveness
Solution Approach 2:
The patent introduces dsRNA molecules as intermediary agents that mediate gene silencing between the therapeutic goal and the complement system. These RNA molecules serve as specific mediators that bind to complementary mRNA sequences of complement components, directing their degradation through the RISC complex, thereby providing a non-invasive pathway to inhibit complement activation
2Reliability
If existing complement therapies are used, then complement-associated diseases are treated, but treatment options are limited and require invasive administration
Solution Approach 1:
The patent replaces invasive mechanical administration methods with molecular-level RNA interference therapy. The dsRNA compositions (including siRNA, shRNA, and antisense RNA) target complement component mRNAs directly within cells, providing effective disease treatment through biochemical mechanisms rather than invasive procedures, thereby improving ease of operation
Solution Approach 2:
The patent employs self-service mechanisms where the introduced dsRNA molecules automatically locate and bind to their complementary target mRNAs within the cell cytoplasm or nucleus. The RISC complex autonomously processes the dsRNA and mediates cleavage of target transcripts without requiring continuous external intervention, enabling sustained therapeutic effect with simplified administration
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The dsRNA agents significantly inhibit C3 expression, leading to decreased C3 protein levels in serum and alleviating symptoms of C3-associated disorders such as cold agglutinin disease, warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria, among others, by reducing hemolysis and inflammation.
Implementation Method 1
iRNA compositions which effect the RNA-induced silencing complex (RISC)-mediated cleavage of RNA transcripts of a complement component C3 gene
Implementation Method 2
dsRNA agents that target and inhibit the expression of the complement component C3 gene through RNA-induced silencing complex (RISC)-mediated cleavage
Data Source
AI summary
The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the complement component C3 gene (C3). The invention also relates to methods of using such RNAi agents to inhibit expression of a C3 gene and to methods of preventing and treating a C3-associated disorder, e.g., cold agglutinin disease (CAD), warm autoimmune hemolytic anemia, and paroxysmal nocturnal hemoglobinuria (PNH), lupis nephritis (LN), bullous pemphigoid, Pemphigus, e.g., Pemphigus vulgaris (PV) and Pemphigus foliaceus (PF), and C3 glomerulopathy.